Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Frequently asked questions
What sector does Protalix BioTherapeutics, Inc (PLX) operate in?
Protalix BioTherapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Protalix BioTherapeutics, Inc (PLX) current stock price?
As of the latest data, Protalix BioTherapeutics, Inc stock price is $2.48, with a previous close of $2.55. Protalix BioTherapeutics, Inc lost -$0.07 in the last trading session, representing a -2.75% loss.
What is Protalix BioTherapeutics, Inc (PLX) current market capitalization?
Protalix BioTherapeutics, Inc market cap is approximately 199.82 million.
What is Protalix BioTherapeutics, Inc (PLX) Earnings Per Share (EPS)?
The trailing EPS is $0.23, and the forward EPS is $0.05.
What is Protalix BioTherapeutics, Inc (PLX) Price-to-Earnings (P/E) ratio?
Protalix BioTherapeutics, Inc current P/E ratio is 10.78, with a forward P/E of 49.6.
What is Protalix BioTherapeutics, Inc (PLX) EBITDA?
Protalix BioTherapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 5.76 million.
Does Protalix BioTherapeutics, Inc (PLX) pay dividends?
No. Protalix BioTherapeutics, Inc does not pay a dividend.
How did Protalix BioTherapeutics, Inc (PLX) perform in its most recent earnings report?
In the last report (June 30, 2026), Protalix BioTherapeutics, Inc posted an EPS surprise of 600% and a revenue surprise of 53.86%.
What is Protalix BioTherapeutics, Inc (PLX) beta (volatility) score?
Protalix BioTherapeutics, Inc has a beta of 0.020, indicating lower volatility than the overall market.
